Fetoscopic Endoluminal Tracheal Occlusion
Purpose
This is a single site pilot trial to study the feasibility of Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in the most severe group of fetuses with congenital diaphragmatic hernia (CDH) at Midwest Fetal Care Center, a collaboration between Allina Health and Children's Minnesota. This procedure aims to increase fetal lung volume before birth and improve survival after birth. This study will enroll 10 pregnant people and their baby who meet study criteria.
Condition
- Hernia, DIaphragmatic, Congenital
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- A subject is defined as a female (18 years or older) who is pregnant. 2. The pregnancy must be a singleton pregnancy. 3. The CDH must be left-sided. 4. The CDH must be severe (Observed to Expected Lung to Head Ratio - O/E LHR - < 25% from U/S measurements). 5. No associated lethal anomalies (other than the CDH), no pathogenic variants on microarray, and no pathologic findings on karyotype. 6. Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects. 7. Gestational age at time of balloon placement between and including 27 weeks 0 days and 29 weeks 6 days. 8. Cervix length longer than 20 mm at pre-balloon placement evaluation. 9. Acceptance of responsibility to stay locally (within 15 minutes) of MWFCC and Children's Minnesota - Minneapolis. 10. Written consent must be obtained. 11. Must meet psychosocial criteria including appropriate family/friend support during stay with balloon in place (cannot stay without additional helper), no current illicit drug use, no over-the-counter drug abuse, and no ineffectively treated DSM-IV diagnoses.
Exclusion Criteria
- Twin or higher order gestation 2. Not able to consent 3. Right-sided or bilateral CDH 4. Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome 5. Maternal isoimmunization or neonatal alloimmune thrombocytopenia 6. Balloon not able to be placed prior to 30 weeks gestation 7. CDH O/E LHR 25% or greater 8. Maternal factors precluding safe fetal surgery (maternal cardiac findings not safe for anesthesia, maternal morbid obesity precluding safe usage of the equipment required for entry into the uterus, spontaneous preterm delivery prior to 36 weeks) 9. Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risks of fetal transmission during procedures 10. Short cervix (20 mm or less) 11. History of incompetent cervix or uterine anomaly predisposing to preterm labor 12. Significant placental abnormalities (abruption, chorioangioma, accrete) known at the time of enrollment and/or surgery 13. History of natural rubber latex allergy 14. No safe or feasible fetoscopic approach to balloon placement 15. Inability to relocate to within 15 minutes of MWFCC/Children's Minnesota
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Device Feasibility
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental FETO therapy |
FETO therapy |
|
Recruiting Locations
Minneapolis, Minnesota 55404
More Details
- Status
- Recruiting
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Detailed Description
This is a single site pilot trial to assess the feasibility and safety of treating the most severe group of fetuses with left CDH with Fetal Endoluminal Tracheal Occlusion (FETO) using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) at Midwest Fetal Care Center (MWFCC), a collaboration between Allina Health and Children's MN. Congenital Diaphragmatic Hernia (CDH) is a condition in which a hole in the baby's diaphragm allows the abdominal organs to move into the chest and limit lung growth. The goal of the FETO device is to block the airway with a balloon-type device, allowing fluid to build up in the lungs and help the unborn baby's lungs grow. Bigger lungs may improve the baby's quality of life. The rationale for fetal therapy in severe CDH is to improve fetal lung growth and therefore neonatal survival. The study will enroll pregnant women that meet study criteria, and their baby. The mother-fetus participant will undergo one procedure for placement of FETO before gestational age 29 weeks 6 days; and a second procedure for removal of the FETO device. The timing for removal of FETO is no later than 35 weeks and 6 days. After delivery, routine care of the baby with CDH will occur within the Children's MN NICU.